Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,878 total articles
i-80 Gold (IAUX) is a developer-producer positioned to re-rate in 2026. Market cap sits around $1.55B, cash per share is about $0.46 and the company recently strengthened its balance sheet with a $160M bought deal. With gold demand at record levels and operational optimization driving margin expansion, i-80 is a high-conviction long for investors w…
H&R Block is trading near its 52-week low with a sub-7x P/E, strong free cash flow and a durable dividend. For patient traders looking for value plus income, HRB offers skewed risk/reward over the next 180 trading days.
Devon Energy looks cheap on headline multiples, but the market has already priced in generous merger synergies, dividend hikes and buybacks. With legal scrutiny, integration risk, and a near-term ex-dividend date, there's a tactical opportunity to short into strength for a mid-term trade (45 trading days). Entry $44.00, target $38.00, stop $47.00.
REalloys (ALOY) is a vertically integrated U.S. rare-earth-to-magnet company with a sub-4M float, a recent upsized $50M offering, and clear catalysts that could push the stock higher over the next 45 trading days. The setup is high-risk but actionable: buy into momentum with a tight stop and a realistic target below the 52-week high to account for …
Evotec (EVO) is trading near its 52-week low with oversold technicals (RSI ~28) while the outsourced biologics and antibody discovery markets are forecast to expand materially. With a market cap just under $1.0B and a PB of ~1.14, the setup favors a tactical long for mean reversion into improving industry tailwinds. This trade idea lays out entry, …
Chewy ($CHWY) is a defensive consumer platform with sticky Autoship demand and improving profitability. At roughly $25.80 today and a market cap near $10.7B, the stock offers a mission-capable risk/reward for a mid-term bounce toward $34.00. This trade plan uses a precise entry, stop and target with a 45-trading-day horizon, framed around cash flow…
MYR Group (MYRG) is a specialty electrical contractor positioned to benefit from accelerating transmission & distribution spend and commercial electrification. Fundamentals — including $232M in free cash flow, a conservative debt profile and improving technicals above the 50-day moving average — set up a mid-term trade. Entry at $272.76, stop at $2…
Grupo Aeroportuario del Pacifico (PAC) trades below its short-term moving averages after a run-in with hurricane-related disruptions and soft passenger traffic. The stock's dividend yield (~3.3%), recent refinancing, and a clear recovery path in passenger volumes argue for a mid-term swing entry on a measured pullback. Trade setup: entry $238.00, s…
Rivian's R2 launch targets the sub-$50k mainstream EV segment and, together with improving gross margins and nascent AI/Autonomy investments, creates a tangible long-term upside while the stock trades at roughly $20.8B market cap. This trade idea is a directional long that assumes a smooth R2 production ramp and margin stabilization; it includes an…
Mastercard is evolving from an interchange-driven payments network into a software-first platform. Recent stablecoin and wallet partnerships validate the strategy; fundamentals remain strong with $17.2B free cash flow and a $462B market cap. This trade idea buys a near-term pullback to $515 with a $600 target and $485 stop for a long-term swing ove…
Infleqtion (INFQ) is a recent public-market entrant building neutral-atom quantum systems for computing, sensing and networking. A fresh integration announcement with NVIDIA NVQLink at GTC 2026 and a sub-$3.0B market cap give the stock asymmetric upside into re-rating events — but execution, capital cadence and noisy price discovery raise real near…
Banco Macro's transition from a high-growth, volatile franchise toward a more 'normal' retail and SME bank has pushed valuation to reasonable territory: P/E ~16.5, P/B ~1.31 and a 10.9% dividend yield. Technicals are oversold and short interest has been coming down, creating a tradeable asymmetric risk/reward for a long position with defined entry,…
The Trade Desk (TTD) has been punished for slowing growth, but several discrete catalysts - OpenAI ad talks, CEO insider buying, broader Kokai rollout and an attractive free cash flow yield - make a re-rating plausible. This trade idea lays out an actionable entry at $27.66, a stop at $24.00 and a target of $40.00 on a mid-term (45 trading days) ho…
Qualcomm's recent selloff has pushed the stock toward oversold technicals while fundamentals remain intact: $12.9B in free cash flow, a 23% ROE, and a $144.7B market cap. We outline an actionable long idea with entry, stop and target levels for investors willing to hold through cyclical noise over the next 180 trading days.
Amphenol reported a strong Q4 and is positioned as a 'picks-and-shovels' supplier to AI, telecom and industrial customers. With solid margins, robust cash generation and meaningful scale after recent acquisitions, the setup supports a mid-term long trade. Valuation is rich relative to historical ranges, so manage risk with a defined stop and a cons…
ePlus (PLUS) is posting healthy operating returns and growing its recurring services base, trading at a reasonable multiple versus earnings and enterprise metrics. The trade: buy around $78.25 with a $92 target over the next 45 trading days, stop at $72.50. Reward-to-risk looks attractive, but negative free cash flow and elevated short activity arg…
Smartphone SoC revenue is cooling, but Qualcomm's breadth across connectivity, automotive, and edge compute gives it a path to re-rate. The shares trade at a reasonable EV/EBITDA and generate strong free cash flow. This trade aims to capture a mid-term recovery as fundamentals and technicals realign.
MELI is trading near $1.76k after recent weakness tied to rising credit provisions and competitive pressure. The business still generates strong free cash flow and boasts an expanding fintech user base. This trade targets a rebound as operating leverage and faster fintech monetization reassert themselves over the next 45 trading days, with tight ri…
Qualcomm's business mix - high-margin licensing revenue plus a resilient chip franchise in connectivity and automotive - keeps the buy case intact even as handset and memory cycles soften. At ~$144B market cap, solid free cash flow ($12.9B trailing) and a 2.55% dividend yield give asymmetric upside with manageable downside. This trade targets a mid…
Abercrombie & Fitch (ANF) offers a compelling risk/reward: strong free cash flow ($384.5M), an enterprise value that still trades cheaply (EV/EBITDA ~3.8) and management returning capital via double-digit buybacks. We upgrade to Strong Buy and lay out a concrete trade plan for a 180-trading-day position.
Shoe Carnival (SCVL) is cheap, cash-rich and executing store-level initiatives that are starting to show in margins. The appointment of Cliff Sifford as interim CEO on 02/25/2026 and a clean balance sheet ($130M+ cash, debt-free) reduce execution risk. For traders willing to tolerate retail volatility, buy into the transition with a clear stop and …
Manulife (MFC) is showing the kind of operating leverage and capital discipline that keeps income-focused and value investors interested. With a market cap of about $56.6B, a P/E of 15.1, and a freshly raised common dividend, the stock looks attractive on a pullback. This trade idea sketches an actionable mid-term buy with strict risk controls and …
IREN Limited is a vertically integrated AI and crypto infrastructure operator with secured power capacity, a large Microsoft contract, and a multi-billion dollar credit facility. Recent headline-driven weakness has opened a mid-term buying opportunity around current levels. This trade idea lays out an entry at the market, a disciplined stop, and tw…
Zevra Therapeutics' initial commercial uptake of MIPLYFFA and a $150M Rare Pediatric Disease Voucher sale materially de-risk the company’s move from clinical-stage to commercial-stage rare disease franchising. With a market cap near $620M and an improving top-line setup, we recommend a tactical long position for investors willing to tolerate biotec…
Atour Lifestyle (ATAT) looks set to produce another quarter of upside versus expectations as travel demand in China remains resilient, the company keeps expanding its hotel network and management is returning cash to shareholders. We lay out a mid-term swing trade (45 trading days) to capture a likely re-rating into the 52-week range supported by d…
